NCT01292161|CompletedPhase 2DMC
Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C
Study of Silymarin for Improving Hepatitis C
Loading search results
Sponsor study identifier
interventional
55
1 country
1
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2006
Actual (reported)Study Completion
September 2006
Actual (reported)The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
September 2006
Actual (reported)September 2006
Actual (reported)February 8, 2011
Actual (reported)February 9, 2011
Actual (reported)Serum aminotransferases (ALT, AST)
The investigators measured serum amino transferases by commercial AST kit,. ALT kits(Bayer Diagnostics,. Tarrytown, NY, USA) at six months after silymarin admission
at six months after admission
HCV-RNA
at six months after admission
Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
Tab 210 mg, 630 mg, daily, six months.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Al-zahra university hospital
Isfahan, Isfahan, Iran
hamid kalantari, A.Professor
Associate Professor,Gasteroentrology department
55 participants (actual enrollment reported by the registry).
First Submitted
February 8, 2011
First Posted
February 9, 2011
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Phase I Trial of Silymarin for Chronic Liver Diseases
Contact the study team to confirm eligibility.
Primary Completion
September 2006
Actual (reported)Study Completion
September 2006
Actual (reported)Last Updated
February 9, 2011
Record last verified: 2006-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: